Retatrutide Injections: UK Guide to Administration, Dosing, and Safety

How to inject retatrutide is a question increasingly asked as interest in this investigational triple hormone receptor agonist grows. Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously, and has shown promising results in Phase 2 and Phase 3 clinical trials. However, it is not yet licensed by the MHRA or approved by NICE for use in the UK. This article explains how subcutaneous injections of retatrutide are administered in clinical trial settings, covering technique, dosing schedules, storage, and safety considerations, while making clear that this medication must not be sourced or self-administered outside an approved clinical trial.

What Is Retatrutide and Its Current Status in the UK

Retatrutide is an unlicensed investigational triple hormone receptor agonist not approved by the MHRA, EMA, or NICE as of June 2025, and is only accessible in the UK through approved clinical trials or tightly controlled MHRA access schemes.

Retatrutide is an investigational triple hormone receptor agonist currently under clinical development. It targets three key receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple mechanism of action is designed to promote reductions in body weight and improve metabolic parameters, including blood glucose control. Phase 2 clinical trial data published in the New England Journal of Medicine (2023) demonstrated substantial weight loss in participants over 48 weeks; changes in lipid profiles were reported as secondary or exploratory outcomes in that trial and should be regarded as preliminary findings only.^[1] These results come from a single early-phase trial and cannot be directly compared with approved therapies in the absence of head-to-head studies.

As of the date this article was last reviewed (June 2025), retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the United Kingdom. It is not approved by NICE, nor is it available through NHS prescribing pathways. The drug remains in Phase 3 clinical trials (see ClinicalTrials.^[3]gov for current registered studies), and no confirmed UK approval timeline has been publicly established. Regulatory status should be reconfirmed at each update, as it may change.

Because retatrutide is not yet licensed in the UK, it is not routinely available for prescribing outside a clinical trial. Pre-licence access routes such as the MHRA Early Access to Medicines Scheme (EAMS) or named-patient unlicensed supply exist in principle, but both are tightly controlled and it is not known whether either is currently available for retatrutide. Further information on these schemes is available on the MHRA website. Any product being sold or marketed as retatrutide outside these frameworks should be treated with extreme caution, as it may be counterfeit, unlicensed, or unsafe. The MHRA advises patients not to source injectable medications from unregulated online suppliers or overseas pharmacies, as doing so carries serious health risks.^[4][5]

This article is intended purely for educational purposes: to inform readers about what retatrutide is, how investigational injectable peptides of this class are typically administered in clinical trial settings, and what safety considerations apply. It does not constitute medical advice, and readers should consult a qualified healthcare professional before considering any injectable medication.

Step-by-Step Guide to Administering a Retatrutide Injection

Retatrutide is given as a subcutaneous injection into the abdomen or outer thigh using a pre-filled pen or syringe, following standard RCN-aligned technique including site rotation, sterile needle use, and immediate sharps disposal.

In clinical trial settings, retatrutide is administered as a subcutaneous injection, meaning it is injected into the fatty tissue just beneath the skin, rather than into a muscle or vein. This is the same route used for other GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), which are licensed in the UK. The following guidance reflects standard subcutaneous injection technique as used in clinical research environments, consistent with Royal College of Nursing (RCN) guidance on subcutaneous injections and NHS patient-facing resources on sharps safety. Any injection must only be performed by trained trial participants acting in accordance with the study device's instructions for use (IFU) and under medical supervision.

Preparation steps:

• Wash hands thoroughly with soap and water for at least 20 seconds.

• Gather all necessary equipment: the pre-filled injection pen or syringe (as supplied by the trial site), a new sterile needle, alcohol swabs, and a sharps disposal container.

• Inspect the medication visually according to the trial protocol and device IFU. Appearance may vary by formulation. Do not use if it appears cloudy, discoloured, or contains visible particles, unless the IFU states otherwise.

• Allow the medication to reach room temperature as directed in the trial device IFU before use.

• Prime the pen or check the device as directed by the trial IFU before each use.

• Do not share pens, syringes, or needles with another person.

Injection technique:

• Select an appropriate injection site: the abdomen (at least 5 cm from the navel) or the outer thigh are suitable for self-administration. The upper arm may be used but generally requires a caregiver or healthcare professional to administer the injection.

• Avoid areas of broken, bruised, scarred, infected, or inflamed skin, and areas with moles or naevi.

• Clean the chosen site with an alcohol swab and allow it to dry completely.

• Pinch a fold of skin gently between your thumb and forefinger.

• Insert the needle at the angle specified in the device IFU (typically 45 to 90 degrees, depending on needle length and body composition).

• Depress the plunger slowly and steadily until the full dose is delivered.

• Withdraw the needle smoothly and apply gentle pressure with a clean swab. Do not rub.

• Do not aspirate before injecting.

• Dispose of the used needle immediately in an approved sharps container. Never recap or reuse needles.

If you are taking anticoagulants (e.g., warfarin) or antiplatelet medicines, discuss injection technique with your trial team, as you may be at increased risk of bruising or bleeding at the injection site.

Rotating injection sites with each dose is essential to prevent localised tissue damage or lipohypertrophy. Keep a record of sites used to assist rotation.

Dosing Schedule, Storage, and Handling Instructions

Retatrutide is investigated as a once-weekly subcutaneous injection with a gradual dose escalation protocol; storage and handling must follow the trial pharmacy and device instructions for use exactly.

In Phase 2 and Phase 3 clinical trials, retatrutide has been investigated as a once-weekly subcutaneous injection. Dosing typically follows an escalation protocol, beginning at a low dose to improve tolerability before gradually increasing to a target maintenance dose over several weeks or months. This titration approach is consistent with other incretin-based therapies and is designed to minimise gastrointestinal side effects during the initiation period.

The NEJM 2023 Phase 2 publication describes several trial arms with differing titration schedules and dose ranges. Because these figures vary by arm and protocol, and because the supplementary appendix of that publication should be consulted for precise details, no specific numeric doses are reproduced here. Dosing must always be determined and supervised by the trial clinical team and must not be extrapolated for use outside a clinical trial.

Missed doses: If a dose is missed, follow your trial team's specific instructions. Do not take a double dose to make up for a missed one.

Regarding storage, investigational medicinal products must be stored exactly as specified by the trial pharmacy and the device IFU. Do not apply general guidance from other products, as storage requirements may differ. If you are unsure, contact your trial team before using the product.

Key handling reminders:

• Follow all handling instructions in the device IFU precisely, as steps such as priming and mixing vary by device.

• Check the expiry date before each use.

• Keep out of reach of children.

• Do not use a pen or syringe that has been dropped or damaged.

• Always use a new, sterile needle for each injection. Never reuse needles.

Proper sharps disposal is a legal and public health requirement in the UK. Used needles must be placed in an approved sharps bin. Sharps bins can be obtained from your GP surgery or trial site, and collection arrangements vary by local authority. Contact your local council or ask your trial team for guidance. NHS guidance on sharps disposal is available on the NHS website (nhs.uk).

Common Injection Site Reactions and When to Seek Help

Mild redness, swelling, bruising, and itching at the injection site are common and self-limiting; seek urgent medical attention for signs of infection, anaphylaxis, pancreatitis, or severe abdominal pain.

As with all subcutaneous injectable medications, retatrutide may cause localised reactions at the injection site. These are generally mild and transient, resolving within a few days without specific treatment. Understanding what is normal versus what requires medical attention is an important aspect of safe participation in any clinical trial.

Common, expected injection site reactions include:

• Redness or erythema at the injection site

• Mild swelling or oedema

• Bruising or haematoma formation

• Itching or mild discomfort

• Small, firm nodules beneath the skin (particularly if sites are not rotated)

These reactions are typically self-limiting. Applying a cool compress after injection and consistently rotating sites can help reduce their frequency and severity.

Systemic side effects observed in retatrutide trials are broadly consistent with the GLP-1 receptor agonist class and include nausea, vomiting, diarrhoea, constipation, decreased appetite, and fatigue. These are most common during dose escalation and often improve over time.

Seek prompt medical attention if you experience any of the following:

• Severe or worsening pain, warmth, or swelling at the injection site, which may suggest infection

• Signs of an allergic reaction: rash, urticaria, facial swelling, difficulty breathing, or anaphylaxis

• Persistent or severe abdominal pain, which may indicate pancreatitis

• Right upper quadrant pain, fever, or jaundice, which may indicate gallbladder disease (e.g., cholelithiasis or cholecystitis), a recognised risk with incretin-class therapies

• Signs of dehydration from persistent vomiting or diarrhoea: reduced urine output, dizziness, or feeling faint on standing, which may indicate acute kidney injury and requires urgent assessment

• Rapid heart rate, dizziness, or fainting

• Symptoms of hypoglycaemia (particularly if taking concomitant insulin or sulphonylureas): shakiness, sweating, confusion, or palpitations

• Any new or worsening visual symptoms, particularly if you have diabetes, as rapid improvement in blood glucose control has been associated with worsening of diabetic retinopathy in some patients^[7][8]

In the UK, patients experiencing a severe or life-threatening reaction should call 999. For urgent non-emergency advice, contact NHS 111. Suspected adverse reactions to medicines used in clinical trials should be reported to the trial team or study sponsor in accordance with the trial protocol. If you are taking a medicine outside a clinical trial and experience a suspected adverse reaction, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Safety Considerations and Medical Supervision in the UK

Retatrutide must only be used within an approved clinical trial under medical supervision; key precautions include a history of pancreatitis, gallbladder disease, pregnancy, and concomitant use of insulin or sulphonylureas.

Because retatrutide is not currently licensed in the UK, the most important safety message is straightforward: this medication should not be self-administered outside of an approved clinical trial or a formal MHRA access scheme overseen by a qualified medical team. It is not known whether any such access scheme is currently available for retatrutide. Attempting to source and self-inject unlicensed peptides purchased online carries significant risks, including exposure to counterfeit or contaminated products, incorrect dosing, and the absence of appropriate medical monitoring.

For those participating in legitimate clinical trials, robust safety oversight is built into the trial protocol. Participants receive regular clinical assessments and laboratory monitoring (including liver function, renal function, and lipase levels, as well as any other tests specified by the trial protocol). This level of supervision is essential given that the long-term safety profile of retatrutide in broader populations is still being established.

Key precautions identified in trial data and relevant to the incretin class include:

• Rodent studies with GLP-1 receptor agonists have shown C-cell changes in the thyroid; the relevance to humans is uncertain.^[13][14] UK Summaries of Product Characteristics (SmPCs) for licensed GLP-1 receptor agonists advise counselling patients to report symptoms that may suggest thyroid neoplasia, such as a neck lump, hoarseness, difficulty swallowing, or shortness of breath. Routine calcitonin or thyroid function testing is not recommended by UK SmPCs. Discuss any personal or family history of thyroid conditions with your trial team.

• History of pancreatitis

• Severe gastrointestinal disease

• Gallbladder disease or a history of cholelithiasis

• Pregnancy or breastfeeding

• Concomitant use of insulin or insulin secretagogues (e.g., sulphonylureas), which may increase hypoglycaemia risk

• Retatrutide, like other incretin-class medicines, may slow gastric emptying, which can affect the absorption of oral medicines taken at the same time. This is particularly relevant for medicines with a narrow therapeutic index. For oral contraceptives, the UK SmPC for tirzepatide (Mounjaro) advises using an additional non-oral contraceptive method for at least 4 weeks after starting treatment and for 4 weeks after each dose increase. Discuss all current medications with your trial team before starting.

Patients in the UK who are interested in accessing retatrutide through a clinical trial can search for active studies via the NIHR 'Be Part of Research' website (bepartofresearch.nihr.ac.uk) or the ClinicalTrials.gov database. A GP or specialist referral may be required to assess eligibility.

Several licensed weight management injectable therapies are available in the UK, including semaglutide (Wegovy, approved by NICE for weight management in eligible adults) and tirzepatide (Mounjaro, licensed in the UK for type 2 diabetes and, subject to current NICE guidance, for weight management in eligible adults).^[18] These have established safety profiles and NICE-aligned prescribing pathways. Availability on the NHS also depends on local commissioning arrangements and individual Integrated Care Board (ICB) pathways, in addition to NICE guidance. Patients seeking treatment for obesity or type 2 diabetes should speak with their GP or a specialist weight management service to explore these approved options. Current NICE technology appraisals and the relevant UK SmPCs, available via the Electronic Medicines Compendium (EMC), provide authoritative guidance on indications and eligibility.

Scientific References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.
3. European Medicines Agency Decision P/0336/2024 — Paediatric Investigation Plan for Retatrutide.
4. MHRA urges public to avoid illegal online weight-loss medicines this New Year.
5. Medicines information — NHS.
6. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial.
7. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.
8. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
9. GLP-1 RAs and Ophthalmic Complications in Patients With Type 2 Diabetes.
10. Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus.
11. Incretin-based drugs and the risk of gallbladder or biliary tract disease.
12. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases.
13. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells.
14. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
15. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
16. Wegovy 0.5 mg solution for injection in pre-filled pen — Summary of Product Characteristics.
17. Mounjaro (tirzepatide) EPAR Product Information.
18. Semaglutide for managing overweight and obesity — TA875.
19. Tirzepatide for managing overweight and obesity — TA1026.
20. Tirzepatide for treating type 2 diabetes — TA924.
21. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
22. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Drugs.
23. GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis.
24. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
25. Lyxumia (lixisenatide) EPAR Product Information.
26. Request clinical waste collection — GOV.UK.

Frequently Asked Questions